Imatinib

  • Imatinib 1
  • Imatinib 2
Product Description

  • Targeted mechanism that selectively inhibits the BCR-ABL tyrosine kinase to disrupt signaling pathways driving abnormal cell growth in chronic myelogenous leukemia and gastrointestinal stromal tumors (first-line).
  • Clinically established with robust trials confirming its ability to control disease progression and improve survival outcomes.
  • Formulated as an oral tablet, ensuring ease of administration in outpatient settings.
  • Demonstrated impact on disease management through significant improvements reported in clinical studies.
  • Supported by extensive peer-reviewed research validating its effectiveness in modern oncology.
  • Exhibits a manageable side-effect profile that can be effectively controlled with appropriate clinical oversight.

    • Read more Show less

    EXAMON Handelsges.m.b.H.

    • Country/Region:
      Austria
    • On CPHI since:
      2024
    • Certificates:
      3
    • Employees:
      100 - 249
    Company types
    Generics/Biosimilars Manufacturer
    Pharmaceutical company
    Primary activities
    API Producer
    Generic APIs producer
    Pharmaceutical Company (generic finished products)
    View company profile
    Categories
    more categories Show less
    Specifications
    • Details
      Oral Film-coated Tablet: 400 mg
    • Selling Points
      Price; Product Features; Product Performance;
    • Oral Formulation
    • Affordability
    • Proven Impact
    • Stringent Quality
  • Model
    400 mg
    • More specifications Fewer specifications

    EXAMON Handelsges.m.b.H.

    • Country/Region:
      Austria
    • On CPHI since:
      2024
    • Certificates:
      3
    • Employees:
      100 - 249
    Company types
    Generics/Biosimilars Manufacturer
    Pharmaceutical company
    Primary activities
    API Producer
    Generic APIs producer
    Pharmaceutical Company (generic finished products)
    View company profile

    More Products from EXAMON Handelsges.m.b.H. (2)

    • Erlotinib-KIMOTAR®

      Product Erlotinib-KIMOTAR®

      • Erlotinib blocks the epidermal growth factor receptor’s tyrosine kinase to suppress tumor cell growth. • Validated efficacy in non-small cell lung cancer (first-line). • Offered in tablet form to facilitate patient-friendly, outpatient treatment. • Underpinned by a wide range of peer-reviewed studies...
    • Gefitinib-GEFISA®

      Product Gefitinib-GEFISA®

      • Used for non-small cell lung cancer (NSCLC) as first-line therapy. Targets EGFR mutations to inhibit tumor growth. •  An EGFR tyrosine kinase inhibition which interrupts receptor signaling to limit tumor cell proliferation. • Robust clinical studies confirm benefits in non-small cell lung and pan...